
    
      This study is a randomized, investigator and participant blinded, sponsor unblinded,
      placebo-controlled, study of the safety, tolerability and pharmacokinetics of TAK-831 in up
      to 48 healthy volunteers, with 8 subjects in each of the 6 cohorts.

      In each cohort, participants will be randomized in a 3:1 ratio to receive TAK-831 or placebo.
      Two formulations, oral suspension and tablet will be tested in this study. Both blood and
      cerebrospinal fluid (CSF) samples will be collected from selected cohorts (CSF cohorts); for
      the rest of the cohorts, only blood samples will be collected (non-CSF cohorts).

      This single-center trial will be conducted in the United States. The overall time to
      participate in this study is 58 days. Participants will make multiple visits to the clinic,
      and 30 days after last dose of study drug for a follow-up assessment.
    
  